Regadenoson是一種A2A腺苷受體激動劑是一種冠狀動脈血管擴張劑。
適應證：Lexiscan是一種藥理學應激劑適用于在不能進行適當運動負荷患者中放射性核素心肌灌注顯像(MPI)。
劑量和用法：Lexiscan推薦的劑量是5 mL (0.4 mg regadenoson)通過迅速靜脈注射；隨后立即用鹽水和放射性藥物沖洗。
禁忌證：有二級或三級AV阻滯，或竇房結功能失調患者不能給予Lexiscan除非患者 有功能良好的人工心臟起搏器
不良反應：對Lexiscan最常見(發生率 ≥ 5%)不良反應是呼吸困難、頭痛、面紅、胸部不適、眩暈、心絞痛、胸痛、和惡心。
藥物相互作用：甲基黃嘌吟類，如，咖啡因和茶堿，可能干擾Lexiscan的活性。 氨茶堿可能用于減輕嚴重和/或對Lexiscan的持久不良反應。
[1]MIYAMOTO MI,VERNOTICO SL,MAJMUNDAR H,et al.Pharmacologic stress myocardial perfusion imaging:a practicalapproach[J].J Nucl Cardiol,2007,14(2):250-255.
[2]PRESS NJ,GESSI S,BOREA PA,et al.Therapeutic potentialof adenosine receptor antagonists and agonists[J].Expert OpinTher Pat,2007,17(8):979-991.
[3]SPICUZZA L,DI MARIA G,POLOSA R.Adenosine in theairways:implications and applications[J].Eur J Pharmcol,2006,533(1-3):77-88.
[4]CERQUEIRA MD.Advances in pharmacologic agents in imaging:new A2A receptor agonists[J].Curr Cardiol Rep,2006,8(2):119-122.
[5]JAROUDI WA,ISKANDRIAN AE.Regadenoson:a new myo-cardial stress agent[J].J Am Coll Cardiol,2009,54(13):1123-1130.
[6]ZHAO G,LINKE A,XU X,et al.Comparative profile ofvasodilation by CVT-3146,a novel A2A receptor agonist,andadenosine in conscious dogs[J].J Pharmacol Exp Ther,2003,307(1):182-189.
[7]TROCHU JN,ZHAO G,POST H,et al.Selective A2A adeno-sine receptor agonist as a coronary vasodilator in conscious dogs:potential for use in myocardial perfusion imaging[J].J CardiovascPharmacol,2003,41(1):132-139.
[8]HAGE FG,HEO J,FRANKS B,et al.Differences in heart rateresponse to adenosine and regadenoson in patients with andwithout diabetes mellitus[J].Am Heart J,2009,157(4):771-776.
[9]GAEMPERLI O,SCHEPIS T,KOEPFLI P,et al.Interaction ofcaffeine with regadenoson-induced hyperemic myocardial bloodflow as measured by positron emission tomography:arandomized,double-blind,placebo-controlled crossover trial[J].JAm Coll Cardiol,2008,51(3):328-329.
[10]ZHAO G,MESSINA E,XU X,et al.Caffeine attenuates theduration of coronary vasodilation and changes in hemodynamicsinduced by regadenoson(CVT-3146),a novel adenosine A2Areceptor agonist[J].J Cardiovasc Pharmacol,2007,49(6):369-375.
[11]LIEU HD,SHRYOCK JC,von MERING GO,et al.Regadenoson,a selective A2A adenosine receptor agonist,causes dose-dependent increases in coronary blood flow velocity in humans[J].J Nucl Cardiol,2007,14(4):514-520.
[12]HENDEL RC,BATEMAN TM,CERQUEIRA MD,et al.Initialclinical experience with regadenoson,a novel selective A2Aagonist for pharmacologic stress single-photon emission computedtomography myocardial perfusion imaging[J].J Am Coll Cardiol,2005,46(11):2069-2075.
[13]CERQUEIRA MD,NGUYEN P,STAEHR P,et al.ADVANCE-MPI Trial Investigators.Effects of age,gender,obesity,anddiabetes on the efficacy and safety of the selective A2A agonistregadenoson versus adenosine in myocardial perfusion imaging:integrated ADVANCE-MPI trial results[J].JACC CardiovascImaging,2008,1(3):307-316.
[14]ISKANDRIAN AE,GARCIA EV,FABER T.Analysis of serialimages:a challenge and an opportunity[J].J Nucl Cardiol,2008,15(1):23-26.
[15]LEAKER BR,O’CONNOR B,HANSEL TT,et al.Safety ofregadenoson,an adenosine A2A receptor agonist for myocardialperfusion imaging,in mild asthma and moderate asthmapatients:a randomized,double-blind,placebo-controlled trial[J].J Nucl Cardiol,2008,15(3):329-336.
[16]THOMAS GS,TAMMELIN BR,SCHIFFMAN GL,et al.Safetyof regadenoson,a selective adenosine A2A agonist,in patientswith chronic obstructive pulmonary disease:a randomized,double-blind,placebo-controlled trial(RegCOPD trial)[J].JNucl Cardiol,2008,15(3):319-328.
[17]Palle, V.P., et al.: J. A. Drug Dev. Res., 50, 64 (2000)。
[18]Gordi, T., et al.: J. Clin. Pharmacol., 47, 825 (2000)
[19]Zhao, G., et al.: J. Cardiovas. Pharmacol., 52, 467 (2000)
[20]Botvinick, E., et al.: J. Nuc. Med. Technol., 37, 14 (2000)
